Johnson & Johnson shares surged approximately 18% over the last 30 days, climbing from $222.89 on June 2 to $263.04 on July 2, 2026. A Guggenheim analyst upgrade with a $270 price target and a $1 billion Firefly Bio acquisition fueled strong investor optimism around the oncology pipeline.

Eli Lilly shares surged approximately 14.1% over the past 30 days, climbing from $1,064.15 on June 2 to $1,213.91 on July 2, 2026. The rally was fueled by a combination of robust quarterly earnings, raised full-year guidance, and accelerating demand for the company’s GLP-1 obesity and diabetes franchises.

Novo Nordisk (NVO) shares surged approximately 20% over the last 30 days, climbing from $42.00 to $50.43. The broader quarterly performance was even stronger, with the stock gaining roughly 38% since early April.

AbbVie shares surged approximately 17.6% over the past 30 days, climbing from $215.40 on May 27, 2026, to $253.35 at the June 26 close, hitting a new all-time high. The rally was fueled by the announced $10.9 billion acquisition of Apogee Therapeutics, strengthening AbbVie's immunology pipeline with an experimental eczema drug.

LLY shares surged +6.67% during regular market trading on June 26, climbing from a prior close of $1,127.69 to $1,202.86. The primary catalyst was the European Medicines Agency's CHMP issuing a positive opinion recommending approval of Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia across all lines of therapy in the EU.

Eli Lilly and Company (LLY) shares rose approximately 14.6% over the past 30 days, driven by sustained momentum in its obesity and diabetes franchises. Over the last quarter, the stock advanced roughly 14.3%, reflecting broader investor confidence in the company’s cardiometabolic pipeline and revenue growth trajectory.

GSK stock declined approximately -14% over the past 30 days, primarily due to a sharp post-Q1 earnings drop amid investor concerns over one-off boosts and general medicines weakness. Over the past quarter, the stock is down around -8%, reflecting volatility after earlier peaks from Q4 strength, offset by recent sector pressures and valuation reassessments.

Gilead Sciences reported Q1 2026 total revenues of $6.96 billion, up 4% year-over-year and beating consensus estimates of $6.91 billion. Non-GAAP diluted EPS came in at $2.03, surpassing expectations of $1.91 and up 12% from $1.81 in Q1 2025.

Analysts expect Q1 2026 revenue of $6.92 billion, up 3.4% from $6.67 billion in Q1 2025. Consensus EPS estimate stands at $1.91 per share, reflecting a 5.5% increase year-over-year based on non-GAAP figures from prior year.

Novo Nordisk is scheduled to report Q1 2026 results on May 6, 2026, before market open. Analysts expect EPS of $0.87, down about 5% year-over-year from Q1 2025's $0.92.

Analysts expect Q1 2026 revenues of approximately $13.8 billion, up slightly from $13.7 billion in Q1 2025. Consensus adjusted EPS estimate is around $0.72-$0.74 per share, down about 20% year-over-year from $0.92 due to product mix shifts and cost pressures.

Analysts expect Q1 2026 revenue of approximately $10.93 billion, a roughly 2.5% decline year-over-year. Consensus adjusted EPS (earnings per share) is forecasted at $1.44-$1.46, reflecting ongoing transition dynamics.

Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.

Analysts expect Q1 2026 revenue of $15.91 billion, up slightly from $15.5 billion in Q1 2025. Consensus earnings per share (EPS) estimate stands at -$1.31, reflecting acquisition-related charges.

Analysts expect Q1 2026 revenue of $17.78 billion, up 39.7% year-over-year from $12.73 billion in Q1 2025. Consensus non-GAAP EPS forecast at $7.26, reflecting robust demand for key products.

GSK plc reported Q1 2026 total sales of £7.6 billion, up 5% at constant exchange rates (CER), slightly ahead of consensus expectations. Core earnings per share (EPS) reached 46.5p, a 9% increase at CER, surpassing analyst estimates of around 43.5p.

AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.

Analysts expect Q1 2026 revenue of approximately $14.8 billion, reflecting about 11% year-over-year growth driven by immunology drugs. Consensus adjusted EPS estimate stands at $2.69, though AbbVie recently guided $2.56–$2.60 after a $744 million IPR&D (intellectual property research and development) charge.

Analysts forecast Q1 2026 revenue of approximately $13.6 billion, a modest 2.5% increase year-over-year. Consensus EPS estimate stands at $2.11 per share, reflecting steady profitability.

Johnson & Johnson reported Q1 2026 sales of $24.1 billion, up 9.9% year-over-year, beating consensus estimates of $23.6 billion. Adjusted EPS came in at $2.70, surpassing expectations of $2.68 and down 2.5% from $2.77 in Q1 2025.